The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis
O. Alejo-Valle, K. Weigert, R. Bhayadia, M. Ng, S. Emmrich, C. Beyer, K. Schuschel, C. Ihling, A. Sinz, M. Flasinski, H. Issa, E. Regenyi, M. Labuhn, D. Reinhardt, M.-L. Yaspo, D. Heckl, J.-H. Klusmann
Abstract
Given the plasticity of hematopoietic stem/progenitor cells, multiple routes of differentiation must be blocked during acute myeloid leukemia pathogenesis - the molecular basis of which is incompletely understood. Here we report that post-transcriptional repression of transcription factor ARID3A by miR-125b is a key event in megakaryoblastic leukemia (AMKL) pathogenesis. AMKL is frequently associated with trisomy 21 and GATA1 mutations (GATA1s), and children with Down syndrome are at a high risk of developing this disease. We show that chromosome 21-encoded miR-125b synergizes with Gata1s to drive leukemogenesis in this context. Leveraging forward and reverse genetics, we uncover Arid3a as the main miR-125b target underlying this synergy. We demonstrate that during normal hematopoiesis this transcription factor promotes megakaryocytic differentiation in concert with GATA1 and mediates TGF{beta}-induced apoptosis and cell cycle arrest in complex with SMAD2/3. While Gata1s mutations perturb erythroid differentiation and induce hyperproliferation of megakaryocytic progenitors, intact ARID3A expression assures their megakaryocytic differentiation and growth restriction. Upon knockdown, these tumor suppressive functions are revoked, causing a dual megakaryocytic/erythroid differentiation blockade and subsequently AMKL. Inversely, restoring ARID3A expression relieves the megakaryocytic differentiation arrest in AMKL patient-derived xenografts. This work illustrates how mutations in lineage-determining transcription factors and perturbation of post-transcriptional gene regulation interplay to block multiple routes of hematopoietic differentiation and cause leukemia. Surmounting this differentiation blockade in megakaryoblastic leukemia by restoring the tumor suppressor ARID3A represents a promising strategy for treating this lethal pediatric disease. Key pointsO_LIRepression of megakaryocytic transcription factor ARID3A by miR-125b synergizes with GATA1s to induce leukemia C_LIO_LIRestoring ARID3A expression relieves megakaryocytic differentiation arrest in megakaryoblastic leukemia C_LI Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=198 SRC="FIGDIR/small/440795v1_ufig1.gif" ALT="Figure 1"> View larger version (49K): org.highwire.dtl.DTLVardef@146c2a7org.highwire.dtl.DTLVardef@9599fdorg.highwire.dtl.DTLVardef@1b0d22borg.highwire.dtl.DTLVardef@1b61447_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of GTF2IRD1 as a novel transcription factor essential for acute myeloid leukemia
Y. Heshmati, G. Turkoz, … J. Walfridsson·bioRxiv·Aug 9, 2022
- CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to Navitoclax
M. Neault, C.-E. Lebert-Ghali, … F. A. Mallette·Cell ReportsPeer-reviewed·Sep 1, 2023
- Direct Binding of miR-155 to FLT3 Regulates Key Cellular Functions in Acute Myeloid Leukemia
Antony Truong, Sarah Warsi, … Amr A. Al-Haidari·bioRxiv·Jan 16, 2026
- RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation
Madeline Y. Mayday, Giulia Biancon, … Diane S. Krause·BloodPeer-reviewed·May 28, 2025
- DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia
Lonneke Verboon, Sonali P. Barwe, … Anilkumar Gopalakrishnapillai·Blood AdvancesPeer-reviewed·Apr 7, 2026
- METTL13 Promotes Pre-Leukemic Transformation and the Development of Pediatric Leukemia
Sabina Enlund, Chae-Eun Lim, … Frida Holm·bioRxiv·Aug 29, 2025